BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
Key Highlights
- ➤AGILITY iliac cohort met its primary endpoint, with a 2.8% failure rate versus 19% goal
- ➤Revello stent achieved 97.2% primary patency at nine months
- ➤98.3% of patients avoided clinically driven target lesion revascularization
- ➤Study enrolled 120 patients across 28 sites; follow-up continues through 36 months
- ➤BD completed enrollment in superficial femoral and proximal popliteal artery cohort
Expert Statements
Sean Lyden, M.D., Chairman of the Department of Vascular Surgery at Cleveland Clinic and global lead principal investigator for AGILITY
“These latest data showed high primary patency and low clinically driven target lesion revascularization in a patient population that included both straightforward and complex iliac lesions.”
Sean Lyden, M.D., Chairman of the Department of Vascular Surgery at Cleveland Clinic and global lead principal investigator for AGILITY
“Results showed the treated arteries remained open in a high percentage of patients, and at nine months, patients also showed changes in disease severity and walking ability.”
Rob Righi, Vice president and general manager of the Vascular Platform, Peripheral Intervention at BD
“These results reflect the continued commitment of BD to advance evidence-based innovation in peripheral vascular care.”
Rob Righi, Vice president and general manager of the Vascular Platform, Peripheral Intervention at BD
“As follow-up continues, the AGILITY study will help further characterize the Revello™ Vascular Covered Stent's performance across patients with peripheral artery disease.”
BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results PR Newswire
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease.
Get started
Create a free account to read the full story.